Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

792 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prep1 prevents premature adipogenesis of mesenchymal progenitors.
Maroni G, Tkachuk VA, Egorov A, Morelli MJ, Luongo R, Levantini E, Blasi F, Magli MC, Penkov D. Maroni G, et al. Among authors: egorov a. Sci Rep. 2017 Nov 14;7(1):15573. doi: 10.1038/s41598-017-15828-1. Sci Rep. 2017. PMID: 29138456 Free PMC article.
Optogenetic technologies in translational cancer research.
Malogolovkin A, Egorov AD, Karabelsky A, Ivanov RA, Verkhusha VV. Malogolovkin A, et al. Among authors: egorov ad. Biotechnol Adv. 2022 Nov;60:108005. doi: 10.1016/j.biotechadv.2022.108005. Epub 2022 Jun 9. Biotechnol Adv. 2022. PMID: 35690273 Review.
Light-Responsive Pt(IV) Prodrugs with Controlled Photoactivation and Low Dark Toxicity.
Spector D, Bubley A, Zharova A, Bykusov V, Skvortsov D, Ipatova D, Erofeev A, Gorelkin P, Vaneev A, Mazur D, Nikitina V, Melnikov M, Pergushov V, Bunin D, Kuzmin V, Kostyukov A, Egorov A, Beloglazkina E, Akasov R, Krasnovskaya O. Spector D, et al. Among authors: egorov a. ACS Appl Bio Mater. 2024 May 2. doi: 10.1021/acsabm.4c00345. Online ahead of print. ACS Appl Bio Mater. 2024. PMID: 38697834
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T, Cottone F, Dunton K, André F, Krop I, Park YH, De Laurentiis M, Miyoshi Y, Armstrong A, Borrego MR, Yerushalmi R, Duhoux FP, Takano T, Lu W, Egorov A, Kim SB. Fehm T, et al. Among authors: egorov a. Lancet Oncol. 2024 May;25(5):614-625. doi: 10.1016/S1470-2045(24)00128-1. Lancet Oncol. 2024. PMID: 38697155 Free article. Clinical Trial.
792 results